Prescription drug · ANDA
brivaracetam NDC 73190-075
Brivaracetam 50 mg/1 · Tablet, Film coated · Oral · AvKARE
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73190-075-60 | 73190007560 | 60 TABLET, FILM COATED in 1 BOTTLE (73190-075-60)Marketed from May 5, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- brivaracetam
- Generic name (nonproprietary)
- brivaracetam
- Active ingredients
- Brivaracetam — 50 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- AvKARE
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 214921
- Marketing start
- Listing expires
- DEA schedule
- CV
- Other FDA classes
- Epoxide Hydrolase Inhibitors (Mechanism)
- Identifiers
- Product ID 73190-075_5115cab3-6f99-9a71-e063-6294a90a694fSPL ID 5115cab3-6f99-9a71-e063-6294a90a694fSPL set ID 5115c5b4-7a23-89f2-e063-6294a90a222aRxCUI 1739768, 1739772, 1739776, 1739780UNII U863JGG2IAUPC 0373190074602
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N473190007560followed by a unit qualifier and the quantityPackage 73190-0075-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 214921
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| brivaracetam | Brivaracetam 25 mg/1 | Tablet, Film coatedOral | AvKARE | 73190-074 |
| brivaracetam | Brivaracetam 100 mg/1 | Tablet, Film coatedOral | AvKARE | 73190-077 |
| brivaracetam | Brivaracetam 75 mg/1 | Tablet, Film coatedOral | AvKARE | 73190-076 |
| brivaracetam | Brivaracetam 75 mg/1 | Tablet, Film coatedOral | Novadoz Pharmaceuticals LLC | 72205-270 |
| brivaracetam | Brivaracetam 10 mg/1 | Tablet, Film coatedOral | Novadoz Pharmaceuticals LLC | 72205-267 |
| brivaracetam | Brivaracetam 25 mg/1 | Tablet, Film coatedOral | Novadoz Pharmaceuticals LLC | 72205-268 |
| brivaracetam | Brivaracetam 50 mg/1 | Tablet, Film coatedOral | Novadoz Pharmaceuticals LLC | 72205-269 |
| brivaracetam | Brivaracetam 100 mg/1 | Tablet, Film coatedOral | Novadoz Pharmaceuticals LLC | 72205-271 |